NEW YORK (GenomeWeb News) – Personalized medicine startup Medomics said this week that it is in discussions with various undisclosed entities to raise $3 million to $4 million to further develop and market its gene sequencing-based diagnostic test for mitochondrial diseases.

Medomics, based in Azusa, Calif., expects to receive a $1 million investment from an undisclosed corporate co-investor if it can raise $2 million to $3 million in financing from additional investors, Steve Sommer, president and founder of Medomics, told GenomeWeb Daily News.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.